Literature DB >> 29702710

Neonatal Morbidities among Moderately Preterm Infants with and without Exposure to Antenatal Corticosteroids.

Sanjay Chawla1, Girija Natarajan1, Dhuly Chowdhury2, Abhik Das2, Michele Walsh3, Edward F Bell4, Abbot R Laptook5, Krisa Van Meurs6, Carl T D'Angio7, Barbara J Stoll8, Sara B DeMauro9, Seetha Shankaran1.   

Abstract

OBJECTIVE: We aimed to compare the rates of "surfactant treated respiratory disease" and other neonatal morbidities among moderately preterm (MPT) infants exposed to no, partial, or a complete course of antenatal corticosteroids (ANS). STUDY
DESIGN: This observational cohort study evaluated MPT infants (290/7-336/7 weeks' gestational age), born between January 2012 and November 2013 and enrolled in the "MPT Registry" of the National Institute of Child Health and Human Development Neonatal Research Network.
RESULTS: Data were available for 5,886 infants, including 676 with no exposure, 1225 with partial, and 3,985 with a complete course of ANS. Among no, partial, and complete ANS groups, respectively, there were significant differences in rates of delivery room resuscitation (4.1, 1.4, and 1.2%), surfactant-treated respiratory disease (26.5, 26.3, and 20%), and severe intracranial hemorrhage (3, 2, and 0.8%). Complete ANS course was associated with lower surfactant-treated respiratory disease, compared with partial ANS (odds ratio [OR] 0.62; 95% confidence interval [CI] 0.52-0.74), and no ANS groups (OR 0.52; 95% CI 0.41-0.66) on adjusted analysis.
CONCLUSION: In MPT infants, ANS exposure is associated with lower delivery room resuscitation, surfactant-treated respiratory disease, and severe intracranial hemorrhage; with the lowest frequency of morbidities associated with a complete course. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29702710      PMCID: PMC6156933          DOI: 10.1055/s-0038-1642059

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  27 in total

1.  Neonatal morbidity in moderately preterm infants: a Swedish national population-based study.

Authors:  Maria Altman; Mireille Vanpée; Sven Cnattingius; Mikael Norman
Journal:  J Pediatr       Date:  2010-09-09       Impact factor: 4.406

2.  A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Authors:  G C Liggins; R N Howie
Journal:  Pediatrics       Date:  1972-10       Impact factor: 7.124

3.  Results of a double-blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome.

Authors:  T A Doran; P Swyer; B MacMurray; W Mahon; G Enhorning; A Bernstein; M Falk; M M Wood
Journal:  Am J Obstet Gynecol       Date:  1980-02-01       Impact factor: 8.661

4.  The use of dexamethasone in women with preterm premature rupture of membranes--a multicentre, double-blind, placebo-controlled, randomised trial. Dexiprom Study Group.

Authors:  R C Pattinson; J D Makin; M Funk; S D Delport; A P Macdonald; K Norman; G Kirsten; C Stewart; D Woods; G Moller; E Coetzee; P Smith; J Anthony; M Schoon; S Grobler
Journal:  S Afr Med J       Date:  1999-08

5.  Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study.

Authors:  M A Kari; M Hallman; M Eronen; K Teramo; M Virtanen; M Koivisto; R S Ikonen
Journal:  Pediatrics       Date:  1994-05       Impact factor: 7.124

6.  Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.

Authors:  Cynthia Gyamfi-Bannerman; Elizabeth A Thom; Sean C Blackwell; Alan T N Tita; Uma M Reddy; George R Saade; Dwight J Rouse; David S McKenna; Erin A S Clark; John M Thorp; Edward K Chien; Alan M Peaceman; Ronald S Gibbs; Geeta K Swamy; Mary E Norton; Brian M Casey; Steve N Caritis; Jorge E Tolosa; Yoram Sorokin; J Peter VanDorsten; Lucky Jain
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

7.  Infants born late/moderately preterm are at increased risk for a positive autism screen at 2 years of age.

Authors:  Alexa Guy; Sarah E Seaton; Elaine M Boyle; Elizabeth S Draper; David J Field; Bradley N Manktelow; Neil Marlow; Lucy K Smith; Samantha Johnson
Journal:  J Pediatr       Date:  2014-12-02       Impact factor: 4.406

8.  Neurodevelopmental outcomes following late and moderate prematurity: a population-based cohort study.

Authors:  Samantha Johnson; T Alun Evans; Elizabeth S Draper; David J Field; Bradley N Manktelow; Neil Marlow; Ruth Matthews; Stavros Petrou; Sarah E Seaton; Lucy K Smith; Elaine M Boyle
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2015-04-01       Impact factor: 5.747

9.  Economic costs associated with moderate and late preterm birth: a prospective population-based study.

Authors:  K A Khan; S Petrou; M Dritsaki; S J Johnson; B Manktelow; E S Draper; L K Smith; S E Seaton; N Marlow; J Dorling; D J Field; E M Boyle
Journal:  BJOG       Date:  2015-07-22       Impact factor: 6.531

10.  Chorioamnionitis and lung injury in preterm newborns.

Authors:  Gustavo Rocha
Journal:  Crit Care Res Pract       Date:  2013-01-10
View more
  2 in total

1.  Contributions of the NICHD neonatal research network's generic database to documenting and advancing the outcomes of extremely preterm infants.

Authors:  Edward F Bell; Barbara J Stoll; Nellie I Hansen; Myra H Wyckoff; Michele C Walsh; Pablo J Sánchez; Matthew A Rysavy; Jenna H Gabrio; Stephanie W Archer; Abhik Das; Rosemary D Higgins
Journal:  Semin Perinatol       Date:  2022-06-10       Impact factor: 3.311

2.  Influence of Timing of Antenatal Corticosteroid Administration on Morbidity of Preterm Neonates.

Authors:  Patrick Morhart; Janis Gärtner; Christel Weiss; Florian Matthias Stumpfe; Ulf Dammer; Florian Faschingbauer; Fabian B Fahlbusch; Matthias W Beckmann; Sven Kehl
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.